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Abstract
Introduction To identify markers and mechanisms of resistance
to adalimumab therapy, we studied global gene expression
profiles in synovial tissue specimens obtained from severe
rheumatoid arthritis (RA) patients before and after initiation of
treatment.
Methods Paired synovial biopsies were obtained from the
affected knee of 25 DMARD (disease-modifying antirheumatic
drug)-resistant RA patients at baseline (T0) and 12 weeks (T12)
after initiation of adalimumab therapy. DAS28-CRP (disease
activity score using 28 joint counts-C-reactive protein) scores
were computed at the same time points, and patients were
categorized as good, moderate, or poor responders according
to European League Against Rheumatism criteria. Global gene
expression profiles were performed in a subset of patients by
means of GeneChip Human Genome U133 Plus 2.0 Arrays, and
confirmatory immunohistochemistry experiments were
performed on the entire cohort.
Results Gene expression studies performed at baseline
identified 439 genes associated with poor response to therapy.
The majority (n = 411) of these genes were upregulated in poor
responders and clustered into two specific pathways: cell
division and regulation of immune responses (in particular,
cytokines, chemokines, and their receptors).
Immunohistochemistry experiments confirmed that high baseline
synovial expression of interleukin-7 receptor α chain (IL-7R),
chemokine (C-X-C motif) ligand 11 (CXCL11), IL-18, IL-18
receptor accessory (IL-18rap), and MKI67 is associated with
poor response to adalimumab therapy. In vitro experiments
indicated that genes overexpressed in poor responders could
be induced in fibroblast-like synoviocytes (FLS) cultures by the
addition of tumor necrosis factor-alpha (TNF-α) alone, IL-1β
alone, the combination of TNF-α and IL-17, and the combination
of TNF-α and IL-1β.
Conclusions Gene expression studies of the RA synovium may
be useful in the identification of early markers of response to
TNF blockade. Genes significantly overexpressed at baseline in
poor responders are induced by several cytokines in FLSs,
thereby suggesting a role for these cytokines in the resistance
to TNF blockade in RA.
ANOVA: analysis of variance; anti-CCP2 antibody: anti-citrullinated cyclic peptide antibody (second-generation test); CCL5: chemokine ligand 5; 
cRNA: complementary RNA; CRP: C-reactive protein; Ct: cycle threshold; CTLA4: cytotoxic T-lymphocyte-associated antigen 4; CXCL11: chemok-
ine (C-X-C motif) ligand 11; DAS: disease activity score; DAS28: disease activity score using 28 joint counts; DAVID: Database for Annotation, Vis-
ualization and Integrated Discovery; DMARD: disease-modifying antirheumatic drug; EULAR: European League Against Rheumatism; FLS: fibroblast-
like synoviocyte; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GCOS: GeneChip Operating Software; GEO: Gene Expression Omnibus; 
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Introduction
Tumor necrosis factor (TNF) antagonists are used routinely in
severe rheumatoid arthritis (RA) patients who failed conven-
tional disease-modifying antirheumatic drug (DMARD) ther-
apy. According to large clinical trials, the three available drugs
(adalimumab, infliximab, and etanercept) display similar effects
in terms of efficacy, tolerability, and side effects [1-5]. These
studies also indicate that about 25% of RA patients treated
with TNF antagonists do not display any significant clinical
improvement. Thus far, however, there are no validated tools
that can predict whether an individual RA patient will respond
to TNF blockade. Yet the identification of poor responders
prior to initiation of therapy would direct the use of alternative
methods of treatment, thereby preventing disease progression
in these patients and saving unnecessary costs.
TNF antagonists interfere with many pathways involved in RA
synovial inflammatory processes; these include local produc-
tion of chemokines and cytokines [6-9], vascular proliferation
and endothelial expression of adhesion molecules [10,11], cell
trafficking into the synovium [8], proliferation of synovial mac-
rophages [12-14], and production of matrix metalloprotein-
ases [15]. Which of these pathways are critical in determining
the clinical improvement associated with the use of TNF-block-
ing agents is still unknown. In the present study, we therefore
wanted to investigate the effects of adalimumab on global
gene expression changes in the RA synovium in order to
obtain a molecular picture of the effects of TNF blockade in
synovial tissue. We also investigated whether clinical, histo-
logical, and molecular characteristics of synovial biopsies at
baseline are associated with response to therapy.
We harvested synovial biopsies in 25 severe RA patients fol-
lowed prospectively before and 12 weeks after initiation of
adalimumab therapy. Global gene expression studies and
pathway analyses were performed in a subset of these
patients, and confirmatory immunohistochemistry experiments
were performed in the entire cohort. We found that adalimu-
mab induces a significant decrease in the expression of genes
involved in cell division in all patients. In responders, we also
observed a decreased expression of genes involved in the reg-
ulation of immune responses (in particular, cytokines, chemok-
ines, and their receptors). Moreover, we demonstrated that
high baseline expression of selected genes from these families
(cell division and regulation of immune responses) is associ-
ated with poor clinical response to therapy, thereby providing
clinicians with potential tools to identify these patients prior to
initiation of adalimumab treatment. Finally, we demonstrated
that genes overexpressed in poor responders are induced in
fibroblast-like synovial cell (FLS) cultures by the addition of
several cytokines or combinations of cytokines: TNF-α, IL-1β,
the association of TNF-α and IL-17, and the association of
TNF-α and IL-1β.
Materials and methods
Patients and synovial biopsies
Twenty-five patients (18 women and 7 men, median age 55.2
years, range 18 to 83 years) with RA were included in the
study. All patients met the American College of Rheumatology
criteria for the diagnosis of RA [16]. Mean disease duration
was 10 years (range 1 to 36 years). All patients had active dis-
ease at the time of tissue sampling and were resistant to con-
ventional therapy. They all had erosive changes imaged on
conventional x-rays of the hands and/or feet. All of them had a
swollen knee at inclusion. Mean baseline serum C-reactive
protein (CRP) level was 29.6 mg/L (range 5 to 122 mg/L), and
mean baseline DAS28 (disease activity score using 28 joint
counts)-CRP (three variables) evaluation was 5.55 (range
4.07 to 8.26). Twenty-two patients had positive anti-citrulli-
nated cyclic peptide (anti-CCP2) antibody titers. All patients
were treated with DMARDs, 23 with methotrexate (median
dose 15 mg/week, range 7.5 to 20 mg/week), and 2 with leflu-
nomide (20 mg/day); 18 of them were treated with low-dose
steroids (prednisolone ≤ 7.5 mg/day). Six patients had been
included in double-blind clinical trials before inclusion in the
present study (1 in a Golimumab versus placebo trial, 3 in a
MapKinase inhibitor versus placebo trial, and 2 in a TNF-α-
converting enzyme [TACE] inhibitor versus placebo trial).
These trials were stopped at least 3 months prior to initiation
of TNF-blocking therapy. All drug dosages were stable from at
least 3 months prior to initiation of TNF-blocking therapy until
completion of the study. No steroid injections were allowed
during the duration of the study.
Adalimumab therapy was initiated at a dosage of 40 mg sub-
cutaneously every other week. Disease activity at baseline (T0)
and 12 weeks after initiation of therapy (T12) was evaluated
using DAS(28)-CRP (three and four variables) scores, and
response to therapy was assessed according to the European
League Against Rheumatism (EULAR) response criteria [17]
that categorize patients as responders (good or moderate)
and non-responders (or poor responders) based on changes
in DAS activity between T0 and T12 and absolute DAS values
at T12.
Synovial biopsies were obtained by needle arthroscopy of the
affected knee of all patients at T0 and T12. For each proce-
dure, four to eight synovial samples were snap-frozen in liquid
nitrogen and stored at -80°C for later RNA extraction. The
same amount of tissue was kept at -80°C for immunostaining
experiments on frozen sections. The remaining material was
fixed in 10% formalin and paraffin-embedded for conventional
optical evaluation and immunostaining of selected markers. All
of the experiments (RNA extraction, histology, and immunohis-
tochemistry) were performed on at least four biopsies har-
vested during every procedure in order to correct for variations
related to the potential heterogeneous distribution of synovial
inflammation. The study was approved by the ethics commit-Available online http://arthritis-research.com/content/11/2/R57
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tee of the Université catholique de Louvain, and informed con-
sent was obtained from all patients.
Fibroblast-like synoviocyte cultures
FLSs were purified from seven additional synovial biopsies
from DMARD-resistant RA patients as previously described
[18]. Briefly, minced synovial fragments were digested in 1
mg/mL hyaluronidase solution (Sigma-Aldrich, St. Louis, MO,
USA) for 15 minutes at 37°C and 6 mg/mL collagenase type
IV (Invitrogen, Paisley, UK) for 2 hours at 37°C. Next, cells
were washed, resuspended in high-glucose Dulbecco's mod-
ified Eagle's medium (Invitrogen) supplemented with 1% anti-
biotics-antimycotics (Invitrogen) and 1% minimum essential
medium sodium pyruvate (Invitrogen), and seeded at 10,000
cells per square centimeter in six-well plates. When the cells
reached confluence, adherent cells were detached using ster-
ile 0.5% trypsin-ethylenediaminetetraacetic acid (Invitrogen)
and used as FLSs between passages 3 and 9. For the
cytokine stimulation experiments, cells were seeded in 24-well
plates at 25,000 per well. Unless stated otherwise, the follow-
ing cytokine concentrations were used: TNF-α (R&D Systems,
Minneapolis, MN, USA) 10 ng/mL, IL-1β (R&D Systems) 10
ng/mL, IL-6 (Peprotech, London, UK) 10 ng/mL, IL-7 (R&D
Systems) 100 ng/mL, and IL-17 (R&D Systems) 50 ng/mL.
After overnight incubation with the indicated cytokines, cells
were harvested and total RNA was extracted using the Nucle-
ospin® RNA II extraction kit (Macherey-Nagel, Düren, Ger-
many). RNA from some experiments was used for microarray
hybridizations while the remaining material was used for cDNA
synthesis and real-time polymerase chain reaction (PCR)
experiments.
Microarray hybridization
Total RNA was extracted from the synovial biopsies using the
Nucleospin® RNA II extraction kit (Macherey-Nagel), including
DNase treatment of the samples. At least 1 μg of total RNA
could be extracted from 12 samples at T0 and from 12 sam-
ples at T12 for further processing. Out of these 12 samples at
T0 and 12 samples at T12, 8 originated from the same
patients and were used in the paired analyses of gene expres-
sion before and after therapy. RNA quality was assessed using
an Agilent 2100 Bioanalyzer and RNA nanochips (Agilent
Technologies, Inc., Santa Clara, CA, USA). All samples had a
28s/18s ratio of greater than 1.8. Labeling of RNA (comple-
mentary RNA [cRNA] synthesis) was performed in accord-
ance with a standard Affymetrix®  procedure (One-Cycle
Target Labeling kit; Affymetrix UK Ltd., High Wycombe, UK);
briefly, total RNA was first reverse-transcribed into single-
stranded cDNA using a T7-Oligo(dT) Promoter Primer and
Superscript II reverse transcriptase (RT). Next, RNase H was
added together with Escherichia coli DNA polymerase I and E.
coli DNA ligase, followed by a short incubation with T4 DNA
polymerase in order to achieve synthesis of the second-strand
cDNA. The purified double-stranded cDNA served as the tem-
plate for the in vitro transcription reaction, which was carried
out overnight in the presence of T7 RNA polymerase and a
biotinylated nucleotide analog/ribonucleotide mix. At the end
of this procedure, the biotinylated cRNA was cleaned and then
was fragmented by a 35-minute incubation at 95°C.
GeneChip® Human Genome U133 Plus 2.0 Arrays (spotted
with 1,300,000 oligonucleotides informative for 47,000 tran-
scripts originated from 39,000 genes) (Affymetrix UK Ltd.)
were hybridized overnight at 45°C in monoplicates with 10 μg
of cRNA. The slides then were washed and stained using the
EukGE-WS2v5 Fluidics protocol on the GeneChip® Fluidics
Station (Affymetrix UK Ltd.) before being scanned on a Gene-
Chip® Scanner 3000. For the initial normalization and analysis
steps, data were retrieved on Affymetrix GeneChip Operating
Software (GCOS). The frequency of positive genes (genes
with a flag present) was between 45% and 55% on each slide.
After scaling of all probe sets to a value of 100, the amplifica-
tion scale was reported to be inferior to 3.0 for all slides. The
signals yielded by the poly-A RNA, hybridization, and house-
keeping controls (glyceraldehyde-3-phosphate dehydroge-
nase [GAPDH] 3'/5' ratio of less than 2) were indicative of the
good quality of the amplification and hybridization procedures.
The same protocol was used for the amplification and the
hybridization of RNA obtained from cultured FLSs. One micro-
gram of total RNA was used in the initial reaction. After the ini-
tial normalization steps on GCOS, the frequency of positive
genes was between 42% and 45% on each slide. The ampli-
fication scale was inferior to 1.5 for all slides, and the GAPDH
3'/5' ratio was inferior to 1.3. The data discussed in this publi-
cation have been deposited in the Gene Expression Omnibus
(GEO) of the National Center for Biotechnology Information
[19] and are accessible through GEO series accession num-
bers [GEO:GSE15602] and [GEO:GSE15615].
Quantitative real-time reverse transcriptase-polymerase 
chain reaction experiments
Quantitative real-time RT-PCR evaluation of lymphotoxin beta
(LTB) [GenBank: NM_002341.1], chemokine ligand 5
(CCL5) [GenBank: NM_002985], and cytotoxic T-lym-
phocyte-associated antigen 4 (CTLA4) [GenBank:
NM_005214.3] gene expression was performed in synovial
biopsies at T0 and T12. cDNA was synthesized from a subset
of RNA that originated from 10 samples at T0 and 8 samples
at T12 using RevertAid Moloney murine leukemia virus RT
(Fermentas, St. Leon-Rot, Germany) and Oligo(dT) primers.
Quantitative RT-PCR was performed on a MyiQ single-color
RT-PCR detection system (Bio-Rad Laboratories, Nazareth
Eke, Belgium) using SYBR Green detection mix. For each
sample, 5 ng of cDNA was loaded in triplicate with 1× SYBR
Green Mix (Applied Biosystems, Foster City, CA, USA) and
the following 10 mM primers: β-actin: 5'-ggcatcgtgat-
ggactccg-3' and 3'-ctggaaggtggacagcga-5'; LTB: 5'-gaggag-
gagccagaaacagat-3' and 3'-tagccgacgagacagtagagg-5';
CCL5: 5'-catattcctcggacaccacac-3' and 3'-gatgtactcccgaac-Arthritis Research & Therapy    Vol 11 No 2    Badot et al.
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ccattt-5'; and CTLA4: 5'-ctcttcatccctgtcttctgc-3' and 3'-gact-
tcagtcacctggctgtc-3'. The melting curves obtained after each
PCR amplification confirmed the specificity of the SYBR
Green assays. Relative expression of the target genes in the
studied samples was obtained using the difference in the com-
parative threshold (ΔΔCt) method. Briefly, for each sample, we
determined a value for the cycle threshold (Ct), which was
defined as the mean cycle at which the fluorescence curve
reached an arbitrary threshold. The ΔCt for each sample was
then calculated according to the formula Cttarget gene - Ctactin;
ΔΔCt values then were obtained by subtracting the ΔCt of a
reference sample from the ΔCt of the studied samples. Finally,
the levels of expression of the target genes in the studied sam-
ples as compared with the reference sample were calculated
as 2-ΔΔCt.
Quantitative evaluation of IL-7R [GenBank: NM_002185], IL-
6 [GenBank: NM_00600], INDO [GenBank: NM_002164],
GTSE1  [GenBank: NM_016426],  CDC2  [GenBank:
NM_001786.3], and MKI67 [GenBank: NM_002417.4] gene
expression was similarly conducted in FLSs using the follow-
ing primers: IL-7R: 5'-ttcttggaggatgcagctaaa-3' and 3'-
aagcccaaccaacaaagagtt-5'; IL-6: 5'-gcccagctatgaactccttct-3'
and 3'-tgaagaggtgagtggctgtct-5'; INDO: 5'-ggtcatggagatgtc-
cgtaa-3' and 3'-accaatagagagaccaggaagaa-5'; GTSE1: 5'-
acgtgaacatggatgacccta-3' and 3'-gttcgggaaccggattattta-3';
CDC2: 5'-ggtcaagtggtagccatgaaa-3' and 3'-ccaggagggata-
gaatccaag-5'; and MKI67: 5'-ccccaaccaaaagaaagtctc-3' and
3'-gactaggagctggagggctta-5'.
Histopathology and immunohistochemistry on paraffin-
embedded sections
Fresh synovial biopsy tissue samples (n = 25 at T0 and n = 25
at T12) were fixed overnight in 10% formalin buffer at pH 7.0
and embedded in paraffin for histological and immunohisto-
chemical analyses. Serial histological sections were stained
with hematoxylin and eosin and analyzed by two observers
(CG and IT) who were blinded to the clinical data. The follow-
ing parameters were evaluated: vascular hyperplasia, perivas-
cular lymphoplasmocytic cell infiltrates, diffuse
lymphoplasmocytic cell infiltrates, follicular structures, thick-
ness of the synovial lining layer, macrophages, polymorphonu-
clear cell infiltrates, fibrinoid necrosis, and fibrosis. A global
semi-quantitative score including the whole biopsy areas was
given for these parameters (0 to 3 scale: 0 indicates absence
and 3 indicates high level). A specific score was assigned for
the hyperplasia of the synovial lining layer: 0 (indicates one or
two cell layers), 1 (three or four), 2 (five or six), and 3 (at least
seven). Inter-observer correlation (Spearman r) was greater
than 85% for every parameter tested except for synovial hyper-
plasia, which scored at 75%.
Immunolabeling experiments were performed using a standard
protocol. After removal of paraffin and inactivation of endog-
enous peroxidases with 0.3% H2O2 for 30 minutes at room
temperature, sections were incubated in 10 mM sodium cit-
rate buffer (pH 5.8) and heated in a bain-marie at 98°C for 75
minutes to retrieve the antigenic sites. Non-specific binding
was blocked by a 30-minute incubation with 50 mM Tris-HCl
(pH 7.4) containing 10% (vol/vol) normal goat serum and 1%
(wt/vol) bovine serum albumin. Sections then were incubated
overnight at 4°C with the primary antibody. The following anti-
bodies were used: CD3 (Neomarkers, Westinghouse, CA,
USA), CD20 (Biocare Medical, Concord, CA, USA), CD68
(DakoCytomation, Glastrup, Denmark), CD15 (Biocare Med-
ica), MKI67 (DakoCytomation), IL-18 (MBL, Nagoya, Japan),
and gp130 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA). After three washes in 50 mM Tris-HCl (pH 7.4), specif-
ically bound antibodies were labeled for 1 hour at room tem-
perature with Envision™ (DakoCytomation), and the activity of
peroxidases was revealed by a 10-minute incubation with 0.5
mg/mL diaminobenzidine in Tris-HCl buffer. As a final step,
sections were washed in tap water and lightly counterstained
with hematoxylin.
Immunohistochemistry on frozen sections
After initial blocking of endogenous peroxidases with a perox-
idase-blocking reagent (DakoCytomation), frozen sections of
the synovial biopsy samples were stained with primary anti-
bodies for the following molecules: interleukin-7 receptor α
chain (IL-7R) (Sigma-Aldrich), chemokine (C-X-C motif) ligand
11 (CXCL11) (also named ITAC, interferon-inducible T-cell
alpha chemoattractant) (Abcam, Cambridge, UK), and IL-18
receptor accessory (IL-18rap) (Abnova, Taipei, Taïwan). After
incubation with the primary antibody, slides were sequentially
incubated with an EnVision horseradish peroxidase (HRP) rab-
bit or mouse secondary antibody conjugated to an HRP-
labeled polymer (Dako EnVision+System; DakoCytomation)
and diaminobenzidene-positive chromagen (DakoCytoma-
tion). The slides were subsequently counterstained with hema-
toxyin for further analyses.
Quantitative scoring of immunostaining
Quantitative analysis of the immunostained sections was per-
formed using ImageJ software [20] in accordance with the
Digital Image Analysis process [21]. Six digitalized pictures
(magnification × 400) were obtained for each slide by two
operators (VB and A-LM) who were blinded to the identity of
the specimens. Each picture included lining and sublining
regions when possible. When the distribution of the staining
was heterogeneous, the pictures were taken in order to be
representative of the globality of the slide. The surface staining
(S) and the surface of the nuclei (N) were determined for each
image, and the area of staining then was normalized by calcu-
lating the ratio of surface staining to nuclei staining.
Statistical analyses
Statistical analyses of the microarray data were first performed
using TMEV 4.0 [22]. Differences in gene expression between
T0 and T12 were evaluated using paired Student t tests afterAvailable online http://arthritis-research.com/content/11/2/R57
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processing of the scaled data for elimination of the genes with
a flag absent in more than half of the samples and selection of
the 8,000 genes that displayed the widest inter-individual var-
iations in the remaining genes. Further statistical analyses
were performed using Genespring® software (Agilent Tech-
nologies, Inc.). For each slide, scaled data were normalized to
the 50th percentile value for each chip and to the median value
for each gene. The data were assessed by analysis of variance
(ANOVA) for identification of differential gene expression at T0
among good, moderate, and poor responders, with the mini-
mal level of differential expression between good and moder-
ate versus poor responders set at 1.5-fold. Data obtained from
the FLS cultures were similarly analyzed on Genespring®,
using the same normalization steps and statistical tests.
Pathway analyses were performed using GOstat [23], an
application that finds statistically overrepresented Gene
Ontology (GO) terms within a group of genes [24]. These
analyses were restricted to the terms inside the 'biological
process' group of gene ontologies. Additional pathway analy-
ses were performed using DAVID (Database for Annotation,
Visualization and Integrated Discovery) [25], an application
that interrogates additional functional annotation databases
(Kegg pathways, BioCarta, and InterPro) and finds overrepre-
sented biological themes within a group of genes.
Results
Clinical responses
Disease activity was prospectively evaluated at baseline (T0)
and 12 weeks after initiation of adalimumab therapy (T12)
based on DAS28-CRP (three variables) score evaluations.
According to EULAR response criteria, 20 patients were
responders at T12 (13 good and 7 moderate responders)
whereas 5 were non-responders to adalimumab therapy (Fig-
ure 1). The use of DAS28-CRP (four variables) scores that
include visual analog scale general health evaluation by the
patient resulted in classification of the same 20 and 5 patients
into responders versus non-responders, respectively. How-
ever, when this index was used among the responders, there
were 11 good and 9 moderate responders.
We investigated whether baseline clinical characteristics were
associated with response to therapy. DAS28-CRP (three var-
iables) scores were not significantly different at baseline in
responders (mean ± standard error of the mean [SEM]: 5.289
± 0.213) and non-responders (mean ± SEM: 4.774 ± 0.186,
P  = 0.34). Similarly, DAS28-CRP (four variables) scores
(mean ± SEM responders: 5.6725 ± 0.984; mean ± SEM
non-responders: 5.066 ± 0.302, P = 0.19), CRP values (mean
± SEM responders: 27.9 ± 7.4 mg/L; mean ± SEM non-
responders: 36.4 ± 21.4 mg/L, P = 0.64), and anti-CCP2 anti-
body titers (mean ± SEM responders: 477.2 ± 122.8 U/mL;
mean ± SEM non-responders: 381.8 ± 208.7 U/mL, P  =
0.72) were not significantly different in responders versus non-
responders at baseline.
Immunohistochemistry studies
First, we evaluated the effects of adalimumab therapy on the
histopathological characteristics of the synovial biopsies har-
vested at T0 in a clinically affected knee and at T12. Semi-
quantitative evaluation and paired comparisons of the biopsies
indicated that adalimumab induced a significant decrease in
the number of infiltrating polymorphonuclear cells between T0
and T12. By restricting the analyses to the biopsies from the
20 patients who responded to therapy, we could find evidence
of a significant decrease in polymorphonuclear cell infiltration,
fibrinoid necrosis, and diffuse lymphoplasmocytic cell infil-
trates (data not shown).
The effects of adalimumab on synovial cell populations were
further investigated by immunohistochemistry. Quantitative
analyses of CD68+, CD15+, CD3+, and CD20+ cells and
paired analyses indicated that adalimumab induced a signifi-
cant decrease in the numbers of CD68+ synovial cells in the
sublining between T0 and T12 in all patients. When we con-
sidered the changes occurring only in the patients who
responded to therapy, we found that adalimumab induced a
significant decrease in the numbers of sublining CD68+,
CD15+, and CD3+ cells. By contrast, there were no changes
in the numbers of CD20+ cells (Figure 2).
We also investigated whether synovial immunohistochemistry
parameters were different among the patients at T0, classified
according to their EULAR response. ANOVAs comparing
poor to moderate and good responders demonstrated that the
amounts of fibrosis and fibrinoid necrosis were significantly
higher in the synovial biopsies from the non-responders at
baseline (data not shown). By contrast, we did not evidence
any significant variation at T0 in the numbers of CD68+, CD3+,
Figure 1
Evolution of disease activity score (DAS) (three variables) in 25 individ- ual rheumatoid arthritis patients before (T0) and 12 weeks after (T12)  initiation of adalimumab therapy Evolution of disease activity score (DAS) (three variables) in 25 individ-
ual rheumatoid arthritis patients before (T0) and 12 weeks after (T12) 
initiation of adalimumab therapy. Patients are categorized into (good or 
moderate) responders or non-responders according to European 
League Against Rheumatism criteria.Arthritis Research & Therapy    Vol 11 No 2    Badot et al.
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CD15+, and CD20+ cells (evaluated by digital quantification)
according to response to therapy.
Effects of adalimumab therapy on synovial gene 
expression profiles
Next, we investigated the effects of adalimumab therapy on
global gene expression profiles of synovial biopsies that were
harvested at T0 and T12. RNA was extracted from eight syno-
vial tissue samples at T0 and T12, labeled, and hybridized in
monoplicates on GeneChip® Human Genome U133 Plus 2.0
slides. According to paired Student t tests, 254 out of 54,675
transcripts were differentially expressed between T0 and T12
in all samples (Additional data file 1); 144 of them were down-
regulated and 110 were upregulated. To investigate whether
these genes clustered in specific pathways, we analyzed the
frequency of the available GO annotations in the list by means
of online data-mining software. We found that genes differen-
tially expressed between T0 and T12 were significantly
enriched in GO families involved in cell division (9% of the GO
annotated genes). If we restricted the analyses to the six
patients who responded to therapy, we found 632 genes dif-
ferentially expressed between T0 and T12. Interestingly, the
latter genes clustered in two distinct families: genes involved
in the regulation of immune responses and genes involved in
the regulation of cell division (Figures 3a and 3b). To fine-tune
these pathway analyses, we interrogated additional functional
annotation databases (Kegg pathways, InterPro, and Bio-
Carta) using DAVID. We found that the genes involved in the
regulation of immune responses further distributed in path-
ways such as signal transduction, T-cell activation, antigen
processing/presentation, and apoptosis. We confirmed our
microarray data by performing real-time PCR evaluations of
Figure 2
Changes in immunohistochemistry parameters in the synovial biopsies of severe rheumatoid arthritis patients Changes in immunohistochemistry parameters in the synovial biopsies of severe rheumatoid arthritis patients. Biopsies were collected prior to (T0) 
(n = 25) and 12 weeks after (T12) (n = 25) initiation of adalimumab therapy. (a) Characteristic images of the stained markers (sublining C68, CD3, 
CD20, and CD15) (original magnification × 400). (b) Ratio of surface staining to staining of the nuclei (S/N). Slides stained for CD68, CD3, CD15, 
and CD20 were analyzed using ImageJ with six digitalized pictures (magnification × 400) obtained for each sample. Open boxes refer to all patients, 
and closed boxes refer to responders. Results are the mean and standard error of the mean of S/N ratio. *P < 0.05; **P < 0.005 versus good and 
moderate responders using Wilcoxon matched-pairs signed rank tests.Available online http://arthritis-research.com/content/11/2/R57
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selected genes from the immune response gene families. As
shown in Figure 3c, we found that LTB, CCL5, and CTLA4
gene expression was significantly lower at T12 as compared
with T0.
Correlation between clinical responses and gene 
signatures
We wondered whether clinical responses to therapy were
associated with different patterns of gene expression at T0.
We used ANOVA tests in order to identify genes differently
Figure 3
Genes differentially expressed before (T0) and 12 weeks after (T12) start of adalimumab in synovial biopsy specimens of rheumatoid arthritis  patients who responded to therapy Genes differentially expressed before (T0) and 12 weeks after (T12) start of adalimumab in synovial biopsy specimens of rheumatoid arthritis 
patients who responded to therapy. Paired Student t tests indicated that 632 (out of 54,675) genes displayed significant differences in expression 
between T0 and T12 in six synovial tissue samples obtained from RA patients who responded to adalimumab therapy. Pathway analyses indicated 
that a significant percentage of these genes clustered into two distinct pathways: genes involved in the regulation of immune responses (a) and 
genes involved in cell division (b). Fold-change values are the mean level of decreased expression at T12 as compared with T0. (c) Real-time reverse 
transcriptase-polymerase chain reaction studies of the expression of selected genes in rheumatoid arthritis synovial biopsy tissue before (T0) (n = 
10) and 12 weeks after (T12) (n = 8) initiation of adalimumab therapy. Samples were loaded in triplicate, and results are the mean and standard 
error of the mean of gene expression, relative to the mean gene expression in a standard sample normalized to 1. *P < 0.05. CCL5, chemokine lig-
and 5; CTLA4, cytotoxic T-lymphocyte-associated antigen 4; LTB, lymphotoxin beta.Arthritis Research & Therapy    Vol 11 No 2    Badot et al.
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expressed at T0 between 12 patients categorized as poor (3),
moderate (4), and good (5) responders. We identified 524
genes that were differentially expressed between the three
groups. In particular, 411 transcripts were found to be upreg-
ulated and 28 were downregulated in poor responders at T0
as compared with the two other groups. GO pathway analyses
indicated that these genes were characterized by a distinct
signature made of genes involved in the regulation of the cell
cycle (28% of the GO annotated genes) and genes involved
in the regulation of immune responses (15% of the GO anno-
tated genes) (Figure 4). Interrogation of additional databases
using DAVID indicated that the genes involved in the regula-
tion of immune responses belong to pathways involved in the
regulation of signal transduction, antigen processing/presen-
tation, T-cell activation, and apoptosis.
To confirm our microarray findings related to differential gene
expression at baseline depending on response to therapy, we
performed immunostaining experiments on the synovial biopsy
specimens obtained from the 25 patients included in the
study. We evaluated the synovial expression of selected mol-
ecules from the immune response group at T0 using specific
antibodies: IL-7R, CXCL11, IL-18, and IL-18rap. MKI67 was
selected as a proliferation marker among the group of genes
involved in the regulation of cell division. Quantitative evalua-
tion of the slides confirmed that synovial expression of IL-7R,
CXCL11, IL-18, IL-18rap, and MKI67 at T0 was significantly
higher in poor as compared with moderate and good respond-
ers (Figure 5). There was no correlation between the digital
quantifications of any of these molecules and cellularity mark-
ers (CD3, CD68, CD20, and CD15), thereby indicating that
their synovial overexpression does not result from a shift in cell
populations in non-responders.
Genes overexpressed in poor responders are induced in 
fibroblast-like synoviocytes by the addition of several 
cytokines
We wondered whether the genes overexpressed at T0 in non-
responders were informative about synovial mechanisms of
resistance to TNF blockade. In particular, we investigated
whether these genes could be induced by TNF-α itself –
which would indicate that their overexpression results from the
overwhelming presence of TNF-α in the synovium – or
whether they could be induced by other pro-inflammatory
cytokines. FLSs were incubated overnight with TNF-α, IL-1β,
IL-6, IL-7, IL-17, and combinations of these cytokines. Real-
time PCR experiments were performed in order to study the
expression of genes known to be overexpressed at baseline in
poor responders (IL-7R,  IL-6,  INDO,  CDC2,  GTSE1, and
MKI67). TNF-α alone, IL-1β alone, and the combination of
TNF-α or IL-1β with IL-17 display stimulatory effects on some
of the genes of this panel, whereas the combination of TNF-α
and IL-1β had a significant stimulatory effect on the whole set
of genes tested (Figure 6). Notably, the effects of the combi-
nation of TNF-α with either IL-17 or IL-1β were synergistic on
Figure 4
Genes differentially expressed at baseline between poor versus moder- ate and good responders to adalimumab therapy Genes differentially expressed at baseline between poor versus moder-
ate and good responders to adalimumab therapy. Five hundred twenty-
four genes were found to be differentially expressed among good, mod-
erate, and poor responders at baseline by analysis of variance (P < 
0.05). Post hoc (Student-Newman-Keuls) tests were used to discrimi-
nate genes that were specifically upregulated (n = 411) or downregu-
lated (n = 28) in poor responders as compared with the two other 
groups. Pathway analyses indicated that these genes were significantly 
enriched in genes involved in the regulation of immune responses (a) 
and genes involved in cell division (b).Available online http://arthritis-research.com/content/11/2/R57
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several targets: IL-6 and CDC2 for TNF-α and IL-17, and IL-
7R, IL-6, INDO, and CDC2 for TNF-α and IL-1β.
Discussion
We studied synovial tissue from DMARD-resistant RA patients
before and 12 weeks after initiation of therapy with adalimu-
mab. Adalimumab therapy resulted in a significant decrease in
the number of CD68+ cells and in the expression of genes
involved in cell division in all patients. In responders, we found
a significant decrease in the numbers of CD68+, CD3+, and
CD15+ cells. From a gene expression point of view, respond-
ers were characterized by significant changes in the expres-
sion of genes involved in cell division and in the regulation of
immune responses. Moreover, ANOVAs performed at baseline
indicated that overexpression of selected genes belonging to
both families was associated with poor response to therapy,
an observation that was confirmed by immunostaining experi-
ments. Finally, in vitro experiments performed in FLSs indi-
Figure 5
Baseline immunostaining for selected synovial markers of response to adalimumab therapy Baseline immunostaining for selected synovial markers of response to adalimumab therapy. Synovial samples of rheumatoid arthritis patients who 
responded or who did not respond to adalimumab therapy were stained at baseline with polyclonal antibodies directed at MKI67, interleukin-7 
receptor α chain (IL-7R), interleukin-18 receptor accessory (IL-18rap), IL-18, and chemokine (C-X-C motif) ligand 11 (CXCL11). (a) Characteristic 
images of the stained markers are shown in responders (n = 20) versus non-responders (n = 5) (original magnification × 400). (b) Ratio of surface 
staining to staining of the nuclei (S/N). Slides were analyzed using ImageJ with six digitalized pictures (magnification × 400) obtained for each sam-
ple. Results are the mean and standard error of the mean of S/N ratio. *P < 0.05, **P < 0.005, ***P < 0.0005 using Wilcoxon matched-pairs signed 
rank tests.Arthritis Research & Therapy    Vol 11 No 2    Badot et al.
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cated that several cytokines and combinations of cytokines
had a significant effect on the expression of a panel of genes
overexpressed in poor responders at T0.
Several studies, aimed at the identification of prognostic mark-
ers of response to TNF blockade in RA, were recently pub-
lished. Transcriptome analyses were performed recently by
Sekiguchi and colleagues [26] in one study and by Lequerré
and colleagues [27] in another study using peripheral blood
mononuclear cells (PBMCs) from RA patients treated with inf-
liximab. In a first set of 6 responders versus 7 non-responders,
the latter identified 41 transcripts associated with response to
therapy in baseline PBMC samples. They confirmed the asso-
ciation of 20 of these transcripts with response to therapy in
an additional set of 20 patients [27]. It is striking, however, that
the genes identified by these authors do not belong to any rel-
evant pathway. It should be stressed in that perspective that
RA is not a systemic disease. The inflammatory mechanisms
targeted by TNF-blocking agents are located in the synovium,
and gene expression profiles of RA PBMCs are not represent-
ative of these synovial tissue-specific pathways. In our previ-
ous studies, we found that transcriptomic analyses performed
on synovial biopsies could discriminate RA from other joint dis-
orders based on the analysis of synovial molecular profiles
only, thereby demonstrating the power of this approach [28].
In this perspective, Lindberg and colleagues [29] investigated
changes in global gene expression profiles in the synovium
from a small group of RA patients before and after therapy with
infliximab. They found a significant decrease in the expression
of 1,058 genes in a subset of four patients with positive syno-
vial immunostaining for TNF-α. These genes were enriched in
families of genes involved in inflammatory processes.
Clinicians would be interested in measurable parameters that
could predict response to TNF blockade prior to its initiation
rather than in modifications of gene expression under therapy.
Thus, van der Pouw Kraan and colleagues [30] performed glo-
bal gene expression profiles in RA synovial tissue obtained in
6 non-responders and 12 responders prior to infliximab ther-
apy. They found that responders were characterized by the
overexpression of genes involved in specific pathways such as
T-cell-mediated immunity, macrophage-mediated immunity,
cytokine- and chemokine-mediated signaling pathways, major
histocompatibility complex II-mediated immunity, and cell
adhesion. Unfortunately, they did not perform any confirmatory
experiment (real-time PCR or immunohistochemistry) in order
to verify the reality of their microarray data [30]. Their results
were also potentially biased by the fact that the synovial biop-
sies from the responders included in their study were charac-
terized by higher percentages of CD3+ and CD163+ cells;
therefore, it is not surprising that genes produced by these
cells are overexpressed in tissues enriched for them. This kind
of bias is very common in gene expression studies performed
in heterogeneous tissues; in these studies, one must be aware
that differences found in gene expression could be due to dif-
ferences in cell populations across the samples rather than to
true differences in pathogenic mechanisms at the single-cell
level.
In the present study, we wanted to increase the validity of such
microarray observations by performing additional RT-PCR and
immunohistochemistry experiments and by linking our data to
potential mechanisms of resistance to TNF blockade in RA.
Our findings about the changes induced by adalimumab in
synovial tissue between T0 and T12 are well in line with previ-
ous data from the literature. In particular, the significant
Figure 6
Genes overexpressed at baseline in poor responders are significantly induced by the combination of tumor necrosis factor-alpha (TNF-α) and inter- leukin-1β (IL-1β) in fibroblast-like synovial cells (FLSs) Genes overexpressed at baseline in poor responders are significantly induced by the combination of tumor necrosis factor-alpha (TNF-α) and inter-
leukin-1β (IL-1β) in fibroblast-like synovial cells (FLSs). FLSs were cultured overnight in the presence of TNF-α (10 ng/mL), IL-1β (10 ng/mL), IL-6 
(10 ng/mL), IL-7 (100 ng/mL), IL-17 (50 ng/mL), or combinations of several of these cytokines. RNA was extracted and real-time reverse tran-
scriptase-polymerase chain reaction evaluation of IL-7R, IL-6, INDO, CDC2, GTSE1, and MKI67 was evaluated in at least four different experi-
ments. Results are expressed as the mean fold change in gene expression and standard error of the mean, relative to the mean gene expression of 
the baseline condition normalized to 1. *P < 0.05, **P < 0.005, ***P < 0.0005 using Wilcoxon signed rank tests.Available online http://arthritis-research.com/content/11/2/R57
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decrease in CD68+ cells is a well-documented characteristic
of TNF-blocking agents in RA. Our gene expression studies
show that adalimumab interferes with two major pathways of
pathophysiological relevance in the RA synovium: regulation of
immune responses and cell proliferation. Activation of these
pathways is a major characteristic of the RA synovium [31,32],
and our gene expression data confirm the well-documented
role of TNF-α and TNF-blocking agents in the regulation of
these pathogenic events.
The main interest of our study is that we identified significant
differences in gene expression profiles at T0 according to the
pattern of clinical response to therapy, while baseline clinical
and histochemical characteristics were not different between
responders and non-responders. In particular, we found that
poor responders are characterized by a significant overexpres-
sion of genes involved in cell division and in the regulation of
immune responses. The differential baseline expression of
selected genes (IL-7R, CXCL11, IL-18, IL-18rap, and MKI67)
among the samples (n = 25) was validated by immunostaining
experiments, thereby qualifying them as potential predictive
markers of response to adalimumab therapy in RA. The confir-
mation of these results in larger numbers of patients could
result in the development of a diagnostic test to guide individ-
ualized therapy.
Strikingly, the genes overexpressed in poor responders are
induced in FLSs by several cytokines, indicating that the
absence of response could be due to the uncontrolled action
of one or several of these cytokines. Earlier studies failed to
demonstrate any correlation between synovial expression of
TNF-α, IL-1β, or other cytokines and clinical response to TNF-
blocking agents [33,34]. However, the biological effect of a
cytokine results not only from the presence of the cytokine
itself, but also from the concentration of its natural inhibitors
(such as soluble TNF receptors or IL-1 receptor antagonists).
Molecular signatures, therefore, are more suited to evaluate
the biological action of a cytokine than raw evaluation of its
synovial concentration.
By indicating that a representative panel of genes overex-
pressed in poor responders are induced in FLSs by TNF-α, IL-
1β, and the combination of TNF-α with either IL-17 or IL-1β,
our results raise the possibility that resistance to TNF block-
ade could be related to the effects of these cytokines on pro-
inflammatory processes in poor responders. However, the
study of gene expression signatures does not allow us to make
strong mechanistic statements. Further experiments, there-
fore, are needed in order to test the in vitro sensitivity of syno-
vial cells from TNF-blocking therapy-resistant patients to
increasing concentrations of TNF-α-, IL-1β-, or IL-17-blocking
agents and finally to identify the mechanisms of resistance to
TNF blockade in RA.
Conclusions
Using high-density oligonucleotide-spotted microarrays and
immunohistochemistry experiments, we identified baseline
markers of response to TNF blockade in a group of RA
patients treated with adalimumab. We demonstrated that the
genes overexpressed in the poor responders are induced by
TNF-α, but also by IL-1β, in FLS cultures and by the combina-
tion of TNF-α with IL-17 or IL-1β, thereby suggesting that one
(or several) of these cytokines plays a role in the mechanisms
of resistance to adalimumab therapy. Our data also allow us to
initiate larger studies in order to confirm the prognostic value
of our markers in individual therapeutic decisions.
Competing interests
A patent application (WO 2008/132176) for the use of syno-
vial markers as predictive markers of response to TNF block-
ade in RA was deposited by the Université catholique de
Louvain (B.R. Lauwerys, B.J. Van den Eynde, Frédéric A.
Houssiau and Valérie Badot). All other authors declare that
they have no competing interests.
Authors' contributions
VB helped to acquire, analyze, and interpret the data and
helped to perform the statistical analyses and to write the man-
uscript. CG helped to acquire, analyze, and interpret the data.
ANT, IT, A-LM helped to acquire the data. BJVdE, PD, and
FAH helped to design the study and contributed to the writing
of the manuscript. BRL helped to design the study and to
acquire, analyze, and interpret the data and helped to perform
the statistical analyses and to write the manuscript. All authors
read and approved the final manuscript.
Additional files
Acknowledgements
This work was supported by an unrestricted grant from Abbott Labora-
tories (Parc Scientifique, Rue du Bosquet 2, B-1348 Louvain-La-Neuve, 
The following Additional files are available online:
Additional file 1
A table listing the genes differentially expressed between 
T0 and T12 in the synovium of adalimumab-treated RA 
patients. Microarray data were analyzed on TMEV 4.0 
after elimination of the genes with a flag absent in more 
than half the samples and selection of the 8,000 genes 
that displayed the widest inter-individual variations. In all 
patients, 254 genes were found to display significant 
differences in expression between T0 and T12 using 
Student's t-tests. Fold changes are the ratio between 
mean expression at T0 above mean expression at T12.
See http://www.biomedcentral.com/content/
supplementary/ar2678-S1.docArthritis Research & Therapy    Vol 11 No 2    Badot et al.
Page 12 of 13
(page number not for citation purposes)
France) and by grants from the Région Wallonne (Biowin), the Fonds de 
la Recherche Scientifique et Médicale (Belgium), and the Fonds Spécial 
de Recherche (Communauté française de Belgique). The authors wish 
to thank Kristel van Landuyt (Laboratorium voor Skeletontwikkeling en 
Gewrichtsaandoeningen, Katholieke Universiteit Leuven) for providing 
protocol and demonstration of FLS cultures.
References
1. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman
MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK: Adalimu-
mab, a fully human anti-tumor necrosis factor alpha mono-
clonal antibody, for the treatment of rheumatoid arthritis in
patients taking concomitant methotrexate: the ARMADA trial.
Arthritis Rheum 2003, 48:35-45.
2. Burmester GR, Mariette X, Montecucco C, Monteagudo-Saez I,
Malaise M, Tzioufas AG, Bijlsma JW, Unnebrink K, Kary S, Kupper
H: Adalimumab alone and in combination with disease-modi-
fying antirheumatic drugs for the treatment of rheumatoid
arthritis in clinical practice: the Research in Active Rheumatoid
Arthritis (ReAct) trial.  Ann Rheum Dis 2007, 66:732-739.
3. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann
RM, Fox RI, Jackson CG, Lange M, Burge DJ: A trial of etaner-
cept, a recombinant tumor necrosis factor receptor:Fc fusion
protein, in patients with rheumatoid arthritis receiving meth-
otrexate.  N Engl J Med 1999, 340:253-259.
4. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS,
Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woody JN: Ran-
domised double-blind comparison of chimeric monoclonal
antibody to tumour necrosis factor alpha (cA2) versus placebo
in rheumatoid arthritis.  Lancet 1994, 344:1105-1110.
5. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfar-
lane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feld-
mann M: Therapeutic efficacy of multiple intravenous infusions
of anti-tumor necrosis factor alpha monoclonal antibody com-
bined with low-dose weekly methotrexate in rheumatoid
arthritis.  Arthritis Rheum 1998, 41:1552-1563.
6. Ulfgren AK, Andersson U, Engstrom M, Klareskog L, Maini RN,
Taylor PC: Systemic anti-tumor necrosis factor alpha therapy
in rheumatoid arthritis down-regulates synovial tumor necro-
sis factor alpha synthesis.  Arthritis Rheum 2000,
43:2391-2396.
7. Barrera P, Joosten LA, den Broeder AA, Putte LB van de, van Riel
PL, Berg WB van den: Effects of treatment with a fully human
anti-tumour necrosis factor alpha monoclonal antibody on the
local and systemic homeostasis of interleukin-1 and TNF-
alpha in patients with rheumatoid arthritis.  Ann Rheum Dis
2001, 60:660-669.
8. Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ,
McCloskey R, Feldmann M, Maini RN: Reduction of chemokine
levels and leukocyte traffic to joints by tumor necrosis factor
alpha blockade in patients with rheumatoid arthritis.  Arthritis
Rheum 2000, 43:38-47.
9. Catrina AI, af Klint E, Ernestam S, Catrina SB, Makrygiannakis D,
Botusan IR, Klareskog L, Ulfgren AK: Anti-tumor necrosis factor
therapy increases synovial osteoprotegerin expression in
rheumatoid arthritis.  Arthritis Rheum 2006, 54:76-81.
10. Ballara S, Taylor PC, Reusch P, Marme D, Feldmann M, Maini RN,
Paleolog EM: Raised serum vascular endothelial growth factor
levels are associated with destructive change in inflammatory
arthritis.  Arthritis Rheum 2001, 44:2055-2064.
11. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody
JN: Deactivation of vascular endothelium by monoclonal anti-
tumor necrosis factor alpha antibody in rheumatoid arthritis.
Arthritis Rheum 1996, 39:1082-1091.
12. Tak PP, Taylor PC, Breedveld FC, Smeets TJ, Daha MR, Kluin PM,
Meinders AE, Maini RN: Decrease in cellularity and expression
of adhesion molecules by anti-tumor necrosis factor alpha
monoclonal antibody treatment in patients with rheumatoid
arthritis.  Arthritis Rheum 1996, 39:1077-1081.
13. Smeets TJ, Kraan MC, van Loon ME, Tak PP: Tumor necrosis fac-
tor alpha blockade reduces the synovial cell infiltrate early
after initiation of treatment, but apparently not by induction of
apoptosis in synovial tissue.  Arthritis Rheum 2003,
48:2155-2162.
14. Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermans-
son Y, Klareskog L, Ulfgren AK: Evidence that anti-tumor necro-
sis factor therapy with both etanercept and infliximab induces
apoptosis in macrophages, but not lymphocytes, in rheuma-
toid arthritis joints: extended report.  Arthritis Rheum 2005,
52:61-72.
15. Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog L, Ulf-
gren AK: Anti-tumour necrosis factor (TNF)-alpha therapy
(etanercept) down-regulates serum matrix metalloproteinase
(MMP)-3 and MMP-1 in rheumatoid arthritis.  Rheumatology
(Oxford) 2002, 41:484-489.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper
NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr,
Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT,
Wilder RL, Hunder GG: The American Rheumatism Association
1987 revised criteria for the classification of rheumatoid arthri-
tis.  Arthritis Rheum 1988, 31:315-324.
17. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, Putte
LB van de, van Riel PL: Development and validation of the Euro-
pean League Against Rheumatism response criteria for rheu-
matoid arthritis. Comparison with the preliminary American
College of Rheumatology and the World Health Organization/
International League Against Rheumatism Criteria.  Arthritis
Rheum 1996, 39:34-40.
18. De Bari C, Dell'Accio F, Tylzanowski P, Luyten FP: Multipotent
mesenchymal stem cells from adult human synovial mem-
brane.  Arthritis Rheum 2001, 44:1928-1942.
19. Gene expression omnibus   [http://www.ncbi.nlm.nih.gov/geo]
20. ImageJ: Image processing and analysis in Java   [ h t t p : / /
rsb.info.nih.gov/ij/index.html]
21. Haringman JJ, Vinkenoog M, Gerlag DM, Smeets TJ, Zwinderman
AH, Tak PP: Reliability of computerized image analysis for the
evaluation of serial synovial biopsies in randomized controlled
trials in rheumatoid arthritis.  Arthritis Res Ther 2005,
7:R862-R867.
22. TIGR Multiexperiment Viewer   [http://www.tm4.org/mev.html]
23. GOStat   [http://gostat.wehi.edu.au]
24. Beissbarth T, Speed TP: Gostat: find statistically overrepre-
sented Gene Ontologies within a group of genes.  Bioinformat-
ics 2004, 20:1464-1465.
25. DAVID   [http://david.abcc.ncifcrf.gov/home.jsp]
26. Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, Ando S,
Ogasawara M, Aburatani H, Kameda H, Amano K, Abe T, Ito S,
Takeuchi T: Messenger ribonucleic acid expression profile in
peripheral blood cells from RA patients following treatment
with an anti-TNF-alpha monoclonal antibody, infliximab.  Rheu-
matology (Oxford) 2008, 47:780-788.
27. Lequerré T, Gauthier-Jauneau AC, Bansard C, Derambure C, Hiron
M, Vittecoq O, Daveau M, Mejjad O, Daragon A, Tron F, Le Loët X,
Salier JP: Gene profiling in white blood cells predicts infliximab
responsiveness in rheumatoid arthritis.  Arthritis Res Ther
2006, 8:R105.
28. Nzeusseu Toukap A, Galant C, Theate I, Maudoux AL, Lories RJ,
Houssiau FA, Lauwerys BR: Identification of distinct gene
expression profiles in the synovium of patients with systemic
lupus erythematosus.  Arthritis Rheum 2007, 56:1579-1588.
29. Lindberg J, af Klint E, Catrina AI, Nilsson P, Klareskog L, Ulfgren
AK, Lundeberg J: Effect of infliximab on mRNA expression pro-
files in synovial tissue of rheumatoid arthritis patients.  Arthritis
Res Ther 2006, 8:R179.
30. Pouw Kraan TC van der, Wijbrandts CA, van Baarsen LG, Rusten-
burg F, Baggen JM, Verweij CL, Tak PP: Responsiveness to anti-
tumour necrosis factor alpha therapy is related to pre-treat-
ment tissue inflammation levels in rheumatoid arthritis
patients.  Ann Rheum Dis 2008, 67:563-566.
31. Imamura F, Aono H, Hasunuma T, Sumida T, Tateishi H, Maruo S,
Nishioka K: Monoclonal expansion of synoviocytes in rheuma-
toid arthritis.  Arthritis Rheum 1998, 41:1979-1986.
32. Watanabe N, Ando K, Yoshida S, Inuzuka S, Kobayashi M, Matsui
N, Okamoto T: Gene expression profile analysis of rheumatoid
synovial fibroblast cultures revealing the overexpression of
genes responsible for tumor-like growth of rheumatoid syn-
ovium.  Biochem Biophys Res Commun 2002, 294:1121-1129.
33. Wijbrandts CA, Dijkgraaf MG, Kraan MC, Vinkenoog M, Smeets
TJ, Dinant H, Vos K, Lems WF, Wolbink GJ, Sijpkens D, Dijkmans
BA, Tak PP: The clinical response to infliximab in rheumatoid
arthritis is in part dependent on pretreatment tumour necrosisAvailable online http://arthritis-research.com/content/11/2/R57
Page 13 of 13
(page number not for citation purposes)
factor alpha expression in the synovium.  Ann Rheum Dis 2008,
67:1139-1144.
34. Buch MH, Reece RJ, Quinn MA, English A, Cunnane G, Henshaw
K, Bingham SJ, Bejarano V, Isaacs J, Emery P: The value of syn-
ovial cytokine expression in predicting the clinical response to
TNF antagonist therapy (infliximab).  Rheumatology (Oxford)
2008, 47:1469-1475.